The ADDF offers funding to researchers in both nonprofit and for-profit organizations for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. Visit our Research Priorities for specific information about our interests.

Our funding is open to:
• Researchers, clinicians, and postdoctoral fellows
• Working in academia and biotechnology companies
• Based in the U.S. and worldwide

The ADDF currently accepts grant proposals through the following RFPs. For returning grantees, we accept proposals for follow-on funding and renewals.

We provide applicants with a streamlined review process—the average time from letter of intent (LOI) decision to award decision is less than four months. For most RFPs, letters of intent are accepted and reviewed on a rolling basis during four cycles each year, corresponding to our four invited full proposal reviews.


Deadline Cycles for Core RFPs:

Letter of Intent
February 17, 2017

Invited Full Proposal
March 10, 2017

Letter of Intent
May 19, 2017

Invited Full Proposal
June 9, 2017

Letter of Intent
July 31, 2017

Invited Full Proposal
September 8, 2017

Letter of Intent
November 17, 2017

Invited Full Proposal
December 8, 2017


Program to Accelerate Clinical Trials (PACT) RFP

Seeks to fund Phase 1 safety testing, Phase 2 biomarker-based, proof-of-concept pilot clinical trials, and IND-enabling studies.


Biomarkers Development RFP

Seeks to support the development and validation of novel and existing biomarkers that will enhance the design and performance of clinical trials for Alzheimer's disease, related dementias, and cognitive aging.


Prevention Beyond the Pipeline RFP

Seeks to support comparative effectiveness research, clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.


Preclinical Drug Discovery RFP

Seeks to fund promising preclinical drug discovery for Alzheimer's disease, related dementias, and cognitive aging.





Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.


Proposals accepted on a rolling basis


Accelerating Drug Discovery for Frontotemporal Degeneration RFP

Seeks to accelerate and support innovative drug discovery programs for FTD in partnership with The Association for Frontotemporal Degeneration.




ADDF-Harrington Scholar Program RFP

Awards recipients with research funding and committed project support with the goal of developing new therapies through a partnership with the Harrington Discovery Institute.




Conference Funding

ADDF supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information email us or apply online.



Support is provided for personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials. Support is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel.


Review Process

  • If your LOI is approved by ADDF scientific staff, you will receive an email with a link to submit your Invited Full Proposal. Before you submit, review the Application Instructions for each RFP. Applicants from biotechnology companies should also review the Mission-Related Investments (MRIs) Policy Statement (PDF).
  • Invited proposals are reviewed externally by members of our Scientific Review Board, which includes scientists from academia and industry with drug discovery expertise. Biotechnology proposals are also reviewed by a member of our Business Review Board.
  • All review Board members sign annual confidential disclosure agreements and must recuse themselves from reviewing any proposals with which they have a conflict of interest.
  • On average, applicants are notified of decisions three months after full proposal submission.
  • Note: Applicants unable to submit the full proposal by the deadline may submit their proposal during the next cycle without submitting a new LOI, unless the proposed work has changed. After two missed deadlines, applicants must submit a new LOI.

All ADDF Governors, officers, and advisory committee members who participate in the selection of recipients for research grant funding are required to annually complete conflict of interest questionnaires to avoid conflicts of interest and maintain high ethical standards.



  • Please note that applicants may only submit one LOI per cycle and one invited full proposal per cycle, but a single academic institution may have multiple applicants apply for funding for different projects within a cycle. Biotechnology companies are limited to the submission of one LOI and one invited full proposal per cycle.
  • Applicants are invited to resubmit proposals up to two times if they are able to address the reviewers' concerns. Resubmissions should include a point-by-point response to the review critiques.


Stay Updated on Upcoming Deadlines and RFP Announcements

Sign up to receive news by email.